跳至主要内容
临床试验/NCT00004467
NCT00004467已完成3 期

Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)23 个研究点 分布在 1 个国家目标入组 173 人开始时间: 1998年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
173
试验地点
23
主要终点
Overall survival rate

研究概览

简要总结

OBJECTIVES:

I. Determine the safety and efficacy of a short course (72 hours) of intravenous acetylcysteine in patients with acute liver failure for whom no antidote or specific treatment is available.

详细描述

PROTOCOL OUTLINE: This is a randomized, multicenter study. Patients are randomized to receive intravenous acetylcysteine or placebo for 72 hours. Treatment must begin within 12 hours of hospitalization. Patients who advance to grade III or IV encephalopathy are eligible for liver transplantation.

Patients are followed at 3 weeks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

N-acetylcysteine (NAC)

Experimental

干预措施: N-acetylcysteine (NAC) (Drug)

结局指标

主要结局

Overall survival rate

时间窗: 3 weeks

次要结局

  • Survival without liver transplantation (Spontaneous Survival(3 weeks)
  • Transplant rate(3 weeks)
  • Length of hospital stay(3 weeks)
  • Number of organ systems showing failure(3 weeks)

研究者

研究点 (23)

Loading locations...

相似试验